ISIS Pharmaceuticals RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifFinanzen.nethttp://www.finanzen.netDAX schließt auf Freitagsniveau -- S&P senkt Ausblick von EFSF-Rating auf negativ -- Wall Street tritt auf der Stelle -- Deutsche Bank sucht neuen Amerika-Chef -- HSBC, Gerry Weber, Lowe's im Fokushttp://www.finanzen.net/nachricht/aktien/DAX-schliesst-auf-Freitagsniveau-S-P-senkt-Ausblick-von-EFSF-Rating-auf-negativ-Wall-Street-tritt-auf-der-Stelle-Deutsche-Bank-sucht-neuen-Amerika-Chef-HSBC-Gerry-Weber-Lowe-s-im-Fokus-1680628<b>Termine vom 27.02.12:</b><br> - FR: Industrieproduktion Januar<br> - USA: Anstehende Hausverk&auml;ufe Dezember<br> - <a href="/aktien/Acme_United-Aktie">Acme United CorpShs </a>: Quartalszahlen<br> - <a href="/aktien/AES-Aktie">AES Corp.</a>: ...http://www.finanzen.net/nachricht/aktien/DAX-schliesst-auf-Freitagsniveau-S-P-senkt-Ausblick-von-EFSF-Rating-auf-negativ-Wall-Street-tritt-auf-der-Stelle-Deutsche-Bank-sucht-neuen-Amerika-Chef-HSBC-Gerry-Weber-Lowe-s-im-Fokus-1680628Sanofi-Aventis schließt Allianz mit Regulus Therapeuticshttp://www.finanzen.net/nachricht/aktien/Sanofi-Aventis-schliesst-Allianz-mit-Regulus-Therapeutics-814796Paris (aktiencheck.de AG) - Der franz&ouml;sische Pharmakonzern <a href="/aktien/Sanofi-Aventis-Aktie">Sanofi-Aventis</a> S.A. gab am Dienstag bekannt, dass er mit der amerikanischen Regulus Therapeutics Inc. eine strategische Allianz vereinbart hat.<!-- ...http://www.finanzen.net/nachricht/aktien/Sanofi-Aventis-schliesst-Allianz-mit-Regulus-Therapeutics-814796Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasishttp://www.finanzen.net/nachricht/Regulus-Therapeutics-and-Collaborators-Publish-Pre-clinical-In-Vivo-Efficacy-Data-on-microRNA-Therapeutics-targeting-microRNA-10b-in-Models-of-Breast-Cancer-Metastasis-764300 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc. today announced the publication of new results in the journal <i>Nature Biotechnology</i> by Regulus scientists and ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-and-Collaborators-Publish-Pre-clinical-In-Vivo-Efficacy-Data-on-microRNA-Therapeutics-targeting-microRNA-10b-in-Models-of-Breast-Cancer-Metastasis-764300Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cellshttp://www.finanzen.net/nachricht/Regulus-Announces-U-S-Allowance-of-Stanford-Patent-Application-Covering-miR-181a-Function-in-Immune-Cells-758630 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application ...http://www.finanzen.net/nachricht/Regulus-Announces-U-S-Allowance-of-Stanford-Patent-Application-Covering-miR-181a-Function-in-Immune-Cells-758630Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21http://www.finanzen.net/nachricht/Regulus-Alnylam-and-Isis-Announce-U-S-Allowance-of-Tuschl-III-Patent-Application-Covering-miR-21-731706 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that the ...http://www.finanzen.net/nachricht/Regulus-Alnylam-and-Isis-Announce-U-S-Allowance-of-Tuschl-III-Patent-Application-Covering-miR-21-731706Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposiumhttp://www.finanzen.net/nachricht/Regulus-Therapeutics-Present-New-Pre-clinical-Data-from-Multiple-Therapeutic-Programs-at-Keystone-Symposium-727657 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-Present-New-Pre-clinical-Data-from-Multiple-Therapeutic-Programs-at-Keystone-Symposium-727657Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Developmenthttp://www.finanzen.net/nachricht/Regulus-Therapeutics-Appoints-Zachary-A-Zimmerman-Ph-D-Director-of-Business-Development-725159 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc., a company developing microRNA therapeutics, today announced the appointment of Zachary A. Zimmerman, Ph.D., as ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-Appoints-Zachary-A-Zimmerman-Ph-D-Director-of-Business-Development-725159Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technologyhttp://www.finanzen.net/nachricht/Regulus-Therapeutics-Receives-Exclusive-License-for-Intellectual-Property-on-Immuno-inflammatory-microRNAs-from-the-California-Institute-of-Technology-717555 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-Receives-Exclusive-License-for-Intellectual-Property-on-Immuno-inflammatory-microRNAs-from-the-California-Institute-of-Technology-717555Regulus Therapeutics Inc. presents: "MicroRNA: The Year in Review and a Look Ahead”http://www.finanzen.net/nachricht/Regulus-Therapeutics-Inc-presents-MicroRNA-The-Year-in-Review-and-a-Look-Ahead-713572 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} .bwtextalignleft {text-align: left} .bwunderlinestyle {text-decoration: underline} --> </style> <!-- sh_cad_1 --> Regulus ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-Inc-presents-MicroRNA-The-Year-in-Review-and-a-Look-Ahead-713572Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Applicationhttp://www.finanzen.net/nachricht/Regulus-Announces-U-S-Allowance-of-Fundamental-microRNA-Therapeutics-Patent-Application-691283 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced ...http://www.finanzen.net/nachricht/Regulus-Announces-U-S-Allowance-of-Fundamental-microRNA-Therapeutics-Patent-Application-691283